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Abstract 
Non-nutritive sweeteners (NNS) are ever more common in the ingredients list of 
food products. They are being used, by the food industry, to bypass the use of 
sugar and, yet, retain the sweetness that allures consumers, who, although 
increasingly health conscious, seek out sweet tasting foods. It is this growing 
presence in our diet, which raises health concerns in the scientific community. 
Even though there are studies that demonstrate the usefulness of NNS in weight 
loss and in glycaemic control, there also exists evidence that chronic usage of 
these substances can lead to the opposite results intended. While the physiologic 
pathways that link NNS with weight gain and insulin resistance remains unclear, 
there is a growing amount of evidence that such a connection does, in fact exist. 
Gut microbiota has been hypothesised as a possible link between NNS 
consumption and obesity and insulin resistance, through its own microbe 
modulation and resulting metabolites. 
These studies could shed new light on the possible hazards of NNS usage and, in 
the future, impact the present recommendations. 
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Resumo 
Os edulcorantes são elementos cada vez mais comuns na lista de ingredientes 
dos produtos alimentares. Estão a ser utilizados pela indústria alimentar de forma 
a evitar o uso de açúcar e, ainda assim, manter o sabor doce que atrai os 
consumidores, que, apesar de apresentarem cada vez mais preocupação com a 
saúde, procuram produtos doces. A presença crescente dos adoçantes não 
nutritivos na nossa dieta leva a que a comunidade científica questione a sua 
segurança para a saúde. Apesar de haver estudos que demonstram benefícios na 
utilização destes edulcorantes para a perda ponderal e para o controlo glicémico, 
existe, também, evidência científica que indica que o uso destas substâncias leva 
a efeitos contrários àqueles pretendidos. Embora os mecanismos fisiológicos que 
ligam os edulcorantes ao aumento ponderal e insulinorresistência ainda não sejam 
claros, há evidência crescente de que tal ligação existe. Pensa-se que a 
microbiota intestinal possa ser o elo entre o consumo de adoçantes não nutritivos 
e a obesidade e insulinorresistência, através da modulação da composição 
microbiológica da mesma e, por consequência, dos seus metabolitos. 
Estes estudos podem elucidar-nos quanto aos perigos que derivam da utilização 
dos adoçantes não nutritivos e, no futuro, ainda ter impacto nas recomendações 
do presente. 
Palavras-chave: adoçantes não nutritivos, insulinorresistência, microbiota 
intestinal 
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Introduction 
When products reach the shelves of the local market, consumers deem them safe, 
but the additives present in food and drink goods could, later in life, have health 
damaging effects. This is where organisations such as the EFSA, the FDA and the 
SCF come in. Additives that must go through a rigorous analysis process before 
its usage in the food and drink industry are sweeteners. This work will focus on 
non-nutritive sweeteners (NNS), which provide a sweetening effect without 
contributing calories to a product. Some NNS are saccharin, sucralose, 
acesulfame potassium and aspartame (Table 1.).  
In the European Union, all sweeteners are exposed to toxicological testing and can 
be tested several times, leading to new findings and new ADIs. 
Table 1. Some non-nutritive sweeteners and their acceptable daily intake as agreed by 
the FDA and the SCF. 
NNS 
ADI FDA(1) 
(per 
mg/kg/bw) 
ADI SCF 
(per 
mg/kg/bw) 
E number a) 
Saccharin 15 0-5(2) 954 
Sucralose 5 0-15(3) 955 
Acesulfame 
potassium 
15 0-15(4) 950 
Aspartame 
50 
 
0-40(5) 951 
a) E number is a code that represents a food additive in the European Union. 
The NNS that will be mentioned throughout this review are saccharin, sucralose 
and aspartame, of which only the latter is metabolised in humans. Despite the lack 
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of metabolism, it is not to be assumed that these sweeteners have no impact on 
the consumers health.  There is a growing body of evidence that NNS influence 
gut microbiota. 
Gut microbiota is a term used to describe the bacteria that take up residence in a 
host’s gastrointestinal tract and is, today, considered to have the function of an 
organ(6, 7). Alteration of this ecosystem can lead to an imbalance in its metabolism 
and, consequently its host’s. Through the uptake of indigestible carbohydrates, the 
gut microbiota produces short-chain fatty acids, who also play a role in the host’s 
health(8). 
This review will focus on studies that link NNS ingestion with changes in gut 
microbiota and the onset of insulin resistance and/or type 2 diabetes. Some 
mechanisms that, in the current literature, have been proposed to explain the link 
between NNS usage and microbiota shifts and glucose intolerance are explored. 
Finally, there is also a mention about SCFAs and their possible role in glucose 
metabolism. 
Theme development 
NNS’ link to obesity and metabolic disease 
NNS are substances that are used to attribute sweetness to food and drink, adding 
little to zero energetic value, while also abiding by the current recommendations 
for lower sugar intake. There are several studies that investigate the link between 
NNS ingestion with obesity and metabolic disorders, though there is still no 
consensus. Sylvetsky et. al. have recently shown, in a randomized clinical trial, 
that many individuals consume NNS unbeknownst to themselves, through 
packaged goods and beverages, hence this ever growing exposure should be 
investigated along with any health risks it might entail(9). 
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Despite the general idea that artificial sweeteners help control and lose weight, 
studies such as those conducted by Stellman and Garfinkel, back in 1986, suggest 
the opposite. Their results from a prospective cohort study which, having followed 
78694 women for a year, depicted that those who used saccharin became 
significantly heavier, compared to their baseline weight(10). Similarly, in 1990, 
Colditz, G.A. et. al. reported results of the Nurses’ Health Study, indicating a dose-
response relationship between the usage of saccharin and weight gain in 
participants who were followed during 8 years(11).  More recent studies, in humans, 
tend to use low calorie sweetened beverages to investigate this association and 
the findings are parallel. Some even present data showing an increased risk in 
developing a number of diseases in NNS consumers, such as metabolic 
syndrome, type 2 diabetes and cardiovascular disease(12, 13). 
This potential connection has yet to gain relevance due to the lack of a solid 
physiological model to explain how NNS can promote weight gain and metabolic 
disorders(14). Still, three possible mechanisms are suggested as explanations for 
metabolic dysregulation as a consequence of NNS intake: deregulation of learned 
responses for energy and glucose control;  interference with sweet-taste receptors 
present in the gut that modulate insulin secretion and glucose absorption; and 
interference of these substances on gut microbiota induces glucose intolerance(15). 
It is established that, in humans, cephalic responses are necessary in order for a 
normal glucose tolerance to be observed(16). Cephalic-phase responses are pre-
absorptive reflexes, just like hormone secretion and thermogenesis, preparing the 
gastrointestinal tract for the arrival of nutrients, while maintaining homeostasis(17). 
The afore mentioned hypothesis that NNS interferes with learned responses, such 
as cephalic responses, has not been tested in human subjects. Thus there is no 
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concrete evidence that artificial sweeteners weaken this mechanism(15). However, 
animal studies do provide data that indicate the existence of said interference. 
Swithers et.al., throughout their research, have suggested the Pavlovian 
conditioning principles as a basis for the theory that usage of these sweeteners 
weakens the association between sweet taste signals and caloric intake. This 
results in the inability of sweet taste being used as a nutritive predictor. In other 
words, the consequence is a lower energy balance capacity due to lack of 
physiological responses(14, 18). The authors found that, in a rat model, there was a 
significant increase in food intake, followed by weight gain and higher adiposity in 
the subjects who consumed NNS. These were compared to the control group, who, 
instead of artificial sweeteners, were privy to glucose in their food and fluids(14). 
In a different study, Swithers et. al. also observed that when comparing a control 
group, whose diet was exempt of artificial sweeteners, with rats consuming water 
sweetened with NNS, the latter demonstrated relative hyperglycaemia after being 
subject to a glucose tolerance test. Subsequently, the glucoregulatory response 
was altered, being associated, by the authors, to decreased incretin hormone 
glucagon like peptide-1 (GLP-1) plasma levels(19). Incretins such as GLP-1 and 
GIP are gut hormones that stimulate pancreatic beta-cells to secrete insulin(20). 
Additionally, there was a different response to how the glucose load was 
administered. When given orally, the afore results were observed; in contrast, 
when the glucose load was infused directly into the subjects’ stomach, there were 
no significant differences in glucose levels between the control group and NNS 
group(19). In this case, the glucoregulatory response might have been spared the 
previous NNS effect, by bypassing oral sweet taste receptors. 
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Regarding NNS modulating insulin secretion and glucose absorption through 
interference with sweet-taste receptors present in the gut, attention has been given 
to the sweet taste receptor subunit T1R3 along with the taste G protein alpha-
gustducin. This is because it is thought that they can be the basis for sugar sensing 
in the bowels. Jang et. al. conducted a study using a rodent model, whose findings 
showed that when mice lacked either alpha-gustducin or T1R3 receptor, their 
incretin response was dulled during a glucose challenge(21). Therefore, alpha-
gustducin and T1R3 receptor are linked to the incretin effect. This last definition 
has its origin in the 1960s and describes how insulin response is greater when an 
oral glucose load is taken orally rather than being administered intravenously, even 
when the loads are measured with the objective of causing equal glucose plasma 
levels(22). Similarly, knockout mice for alpha-gustducin demonstrate a disturbed 
glucose homeostasis not only as a result of glucose tolerance test, but also after 
feeding on chow(21). 
The third hypothesis, mentioned above, on how NNS ingestion might lead to 
metabolic dysregulations is that artificial sweeteners induce glucose intolerance 
through the modulation of the host’s gut microbiota. 
NNS and gut microbiota 
The human gut microbiota encodes a substantially larger number of genes than its 
host and, therefore, has biochemical abilities and metabolic functions that does not 
coincide with the human organism’s capabilities, or surpasses it(23). Examples of 
this is vitamin and amino acid synthesis, bile biotransformation and metabolism of 
oligosaccharides that have alluded digestion, like unabsorbed sugars and 
alcohols, and polysaccharides that are indigestable, such as pectins, gums, 
cellulose, hemicellulose and resistant starches(24-26). This capacity derives from the 
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60000 glycoside hydrolases and polysaccharides lyases that the human gut 
microbiota is privy to and is essential for the afore mentioned pathways, seeing as 
how humans have about 17 of those forms of enzymes(24). From these functions, 
a higher energy harvest is obtained. This is because energy and absorbable 
substrates are recovered for the host and for the gut bacteria themselves, 
permitting their growth and proliferation(27).   
There were early indications that gut microbiota are involved in obesity. In 2005, 
Ley et.al. found that metabolically obese mice, with a leptin gene mutation, 
presented significant differences in gut microbiota composition when compared to 
lean mice. The former had a higher Firmicutes/Bacteroidetes ratio, while 
Bacteroidetes were favoured in the gut of lean mice(28, 29). More recently, intestinal 
microbiota composition has been thought to be involved in the risk of developing 
insulin resistance, a condition that leads to type 2 diabetes(28, 30). It might be that 
an increased monosaccharide uptake, due to differences in the bacterial 
community in the gut, leads to a higher hepatic production of triglycerides, which 
is associated with the onset of insulin-resistance(31). 
 A human case-control study on type 2 diabetes found that bacteria from the 
phylum Firmicutes and the class Clostridia were significantly reduced in patients 
with this disease and there was also a decline in butyrate-producing bacteria (see 
Table 2.)(32). Furthermore, increase of Bacteroides ssp. was observed in diabetic 
rats, in an experimental study about the development of type 1 diabetes(31). 
Further evidence on this matter has been given by Membrez et. al. when they 
subjected genetically and diet induced obese and insulin-resistant mice to two 
weeks of antibiotics, known to suppress cecal bacteria. They found that these 
rodents displayed improvement in fasting plasma glucose levels and oral glucose 
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tolerance testes. These improvements were independent from food intake and 
adiposity, since these factors were equal between the test and control groups(33).  
Table 2. Shifts observed in gut microbiota composition in comparison to healthy 
individuals. Adapted from Clemente Jose C. et. al 2012(34)  
Shifts Increase Decrease 
Bacteria 
Betaproteobacteria Firmicutes 
Bacteroidetes/Firmicutes ratio Clostridia 
Bacteroides – Prevotella* 
Clostridia coccoides - 
Eubacterium rectale* 
Note* - in type 2 diabetes, both the increase and decrease of the mentioned bacteria are 
observed simultaneously 
There is existing evidence that intake of NNS modulates bacteria population in 
animal fecal samples (Table 3). Even though NNS are considered inert, that does 
not rule out the possibility that they interact with the human gut microbiota(35). 
In 2014, Suez et. al. shared their findings that indicate that NNS, especially 
saccharin, strongly affected glycaemic responses in mice and that this metabolic 
dysregulation was mediated by alterations suffered by the gut microbiota. The 
rodents were subjected to 11 weeks of exposure to saccharin, sucralose or 
aspartame and their serum glucose levels were constantly measured. 
Furthermore, the association with the gut microbiota was made, through fecal 
transplantation. Germ-free mice, who had never been exposed to saccharin, 
received fecal microbiota transplant from the rodents who suffered altered glucose 
response due to their saccharin fuelled diet. They also transferred microbiota 
incubated in vitro in the presence of saccharin. The outcome of this experiment 
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was the induction of hyperglycaemic responses to glucose tolerance tests in these 
germ-free mice after said transplants(36). 
Table 3. Impact of some NNS on microbiota; adapted from Suez J et. al. 2015(35) 
NNS 
Study 
subject 
Increase Decrease 
Aspartame Rats 
Total bacteria 
(Enterobacteriacease, 
Clostridiales, 
Roseburia) 
Lactobacilli 
Sucralose 
Culture and 
rats 
 
Total 
anaerobes 
(Bacteroides, 
Bifidobacteria), 
Total aerobes, 
Lactobacilli 
Saccharin  
 
Swine, rats 
and mice 
Total aerobes, 
Lactobacilli, 
Enterobacteriaceae, 
Bacteroides, 
Clostridiales 
Lactobacilli and 
Clostridiales 
 
 This same group of researchers proceeded to study the glycaemic response in 
humans. Seven volunteers, who did not regularly consume NNS, were subjected 
to a daily dose of saccharin that matched the FDA’s maximum daily intake (Table 
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1.), during a week. They also performed daily glucose tolerance tests, ingesting 75 
grams of glucose. The results suggest that regular saccharin ingestion alters 
glycaemic response, because most of the subjects showed increased glycaemia. 
The microbiota fecal transplant was also used with the human subjects and the 
findings were consistent with those from their animal model, where stools from the 
human responders induced glucose intolerance in germ-free mice(36). This study 
does strongly demonstrate that some NNS change the composition of the host’s 
microbiota and that such alterations can lead to insulin resistance, although the 
question remains about how this alteration brings about said consequence. Since 
these sweeteners are seen to modulate the gut bacterial community, it could be 
that a dysbiotic state resulting from this could also lead to changes in SCFA 
production. 
SCFAs and dysbiosis 
Dysbiosis represents an impaired microbiota or, in other words, a disrupted 
microbiome, and it has been associated with insulin resistance(37).  Gathering from 
the various studies mentioned in this review, we may conclude that NNS ingestion 
can, possibly, disrupt the gut microbiota and, consequently, induce insulin 
resistance and, later on type 2 diabetes. As the bacterial community in a host’s 
intestine shift, so might the production of short-chain fatty acids. 
Fermentation of dietary fibres, in the colon, produces metabolites like SCFAs 
which include, primarily, acetate, propionate and butyrate, who are mostly 
produced in the caecum and proximal colon and they are found in a faecal molar 
ratio of 3:1:1, respectively(38, 39). These metabolites play a role in pathophysiology 
of obesity and metabolic syndrome since they regulate energy intake, energy 
harvest and are energy substrates themselves, and therefore influence body 
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weight(40). They also inhibit histone deacetylases and activate G-coupled 
receptors(38).  Additionally, mechanisms that associate SCFAs with type 2 diabetes 
have been proposed that influence adipose tissue function, lipid storage, 
inflammatory profile and liver and skeletal muscle energy metabolism(41-43). This is 
evidenced by many studies, and an example is the one done by Vrieze et. al.. 
Here, in a single blinded randomized control trial, obese human subjects were 
treated with two antibiotics and one of them, vancomycin – attacks gram-positive 
bacteria – modulated the gut microbiota by decreasing its diversity. This impacted 
the bile acid and glucose metabolism, since peripheral insulin sensitivity was 
decreased(44). Other than that, these same authors, in a double-blinded 
randomized trial, transferred faecal microbiota from lean donors to individuals with 
metabolic syndrome and found that there was an increase of butyrate-producing 
bacteria and improved peripheral insulin sensitivity(45). 
Studies such as one conducted by Freeland et. al, in a single-blinded randomised 
cross-over trial, observed that humans receiving rectal or intravenous perfusions 
of acetate demonstrated higher serum concentrations of PYY (peptide YY) and 
GLP-1(46). In turn, propionate supplementation, when administered to healthy 
women, reduced fasting glucose levels during oral glucose tolerance tests, as well 
as increased insulin response(47).  
Butyrate is known to be the main energy source for the colonocytes, consequently 
being the only out of the three SCFAs mentioned to be absorbed locally. Butyrate 
is the most studied SCFA and, possibly because of that, is the one most linked to 
health benefits(38). Such an example is given by Qin et. al. found indication that 
patients with type 2 diabetes had some degree of dybiosis and decreased number 
of bacteria who produce butyrate(32). 
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SCFAs seem to exert benefits and protection of glucose metabolism. Bestens et. 
al. suggest that these metabolites provide protection against obesity and insulin 
resistance, when subjects are on a high-fat diet, through downregulation of 
PPARγ. The authors carried out in vitro and in vivo experiments and they propose 
that downregulation of PPARγ induced by SCFAs activates a pathway - UCP2-
AMPK-ACC – this permits the transition, in adipose and liver tissue, from 
lipogenesis to fat oxidation, which may reduce body weight and improve insulin 
sensitivity(41). 
Critical analysis and conclusion 
The amount of evidence linking NNS consumption, altered gut microbiota and 
insulin resistance – or type 2 diabetes – is abundant. We must, however, recognize 
that many studies have their limitations and confounders that warp the findings. 
The influence of the factors in question, throughout this review, are, in many cases, 
impacted by the characteristics of the animals or human subjects, such as their 
sex, diet, genetic predisposition towards obesity and/or type 2 diabetes and, also, 
their state at the onset of the experiments. 
Although the negative impact of NNS ingestion has been emphasized, there do 
exist numerous studies that show the efficacy of these substances in weight 
control, though few compare NNS intake with a control group who is not subjected 
to non-caloric sweeteners. In fact, many studies, actually, rely on the comparison 
between subjects consuming NNS to those consuming caloric sweeteners(48). A 
hypothesis worth mentioning is the possible reverse causality in many studies on 
NNS and microbiota. This is because human subjects who are already obese or 
suffer from metabolic syndrome tend to use artificial sweeteners. 
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The study from Suez et. al. is the most recent about the NNS impact on microbiota 
and insulin resistance and has the potential to be the stepping stone for further 
findings. They took their experiment a step farther by subjecting humans to the 
trials they set on their animal model. However, there is a limitation that can call 
their results into question. The fact that their human trial lacked a control group for 
the exposure of saccharin, weakens their conclusions. Because there is no control 
group, we cannot know if such a group would also display changes in glucose 
metabolism or even if their stools, transplanted into germ-free mice, would have 
caused glucose intolerance. 
Another study that might warrant attention is the aforementioned trial conducted 
by Qin et. al.. Although they observed a decline in certain gut bacteria and 
production of butyrate in patients with type 2 diabetes, they also alert to the fact 
that the microbiota of said patients only displayed a limited deviation from the 
control groups. This calls into question whether an altered microbiota plays a role 
or not in this disease. 
In relation to the studies that focus on SCFAs, they tend to measure these 
metabolites through stool analysis, but it has been shown that SCFAs uptake 
rather than their caecum concentrations can be correlated with dietary 
physiological effects(49). Also related to this topic, long-term exposure to dietary 
fibre and, therefore, SCFA production has failed to demonstrate benefits on 
glucose homeostasis(50, 51). One cannot deny, however, the possibility of a role of 
SCFA for prevention or counteraction of obesity and insulin resistance, but seeing 
as how most data comes from animal or in vitro studies, the clinical relevance in 
humans is still not well established. 
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This chapter is not meant to debunk the evidence mentioned throughout the work, 
but rather to alert that all and any findings should be interpreted with caution and 
that there is a need for large scale randomised controlled trials. Biologically 
relevant doses of sweeteners should be used and the molecular mechanisms 
should be further investigated so that it can become clearer whether NNS does 
impact the gut microbiota and if this, through SCFA production or other pathway, 
can amount to the development of type 2 diabetes. 
In conclusion, care must be applied by health professionals when suggesting 
sucrose to be substituted by NNS. As was mentioned, the food and drink industry 
are ever more reliant on these substances in order to curtail sugar taxes and health 
aware consumers. Therefore, in addition to the sweetener applied in homemade 
drinks, there must be considered the deserts, beverages and snacks that patients 
will resort to when trying to control their weight and/or diabetes. Another approach 
might consist on the insistence of taste education, where the patient can lower 
his/her dependence on sweet tasting foods. 
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